NUVL241220P130000
- 22.25
- 0.000.00%
Nuvalent Newsroom
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
J.P. Morgan Reaffirms Their Buy Rating on Nuvalent (NUVL)
Express News | Nuvalent Inc : JP Morgan Cuts Target Price to $121 From $125
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
Nuvalent's Promising ALK and ROS1 Programs Drive Buy Rating Amid Strong Financial Position and Upcoming Trials
TD Cowen Maintains Nuvalent(NUVL.US) With Buy Rating
BMO Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $134
Stifel Maintains Nuvalent(NUVL.US) With Buy Rating, Cuts Target Price to $132
Nuvalent Is Maintained at Outperform by BMO Capital
Nuvalent Analyst Ratings
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $100 to $134
Nuvalent Reports Q3 EPS ($1.28), Consensus (94c)
Nuvalent Price Target Raised to $134 From $132 at BMO Capital
Barclays Remains a Buy on Nuvalent (NUVL)
Nuvalent Reports Q3 2024 Progress and Financials
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Nuvalent (NUVL)
Nuvalent | 8-K: Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
Nuvalent: Strategic Progress and Pipeline Advancements Solidify Buy Rating
Nuvalent | 10-Q: Q3 2024 Earnings Report
Express News | Nuvalent Inc : Piper Sandler Raises Target Price to $102 From $100